IMGN [NASD]
ImmunoGen, Inc.
Index- P/E- EPS (ttm)-0.60 Insider Own0.10% Shs Outstand253.26M Perf Week-6.53%
Market Cap778.51M Forward P/E- EPS next Y-0.74 Insider Trans0.00% Shs Float219.58M Perf Month-28.97%
Income-129.40M PEG- EPS next Q-0.21 Inst Own89.20% Short Float7.72% Perf Quarter-29.39%
Sales92.20M P/S8.44 EPS this Y-168.30% Inst Trans2.52% Short Ratio4.14 Perf Half Y-30.08%
Book/sh1.21 P/B2.96 EPS next Y11.00% ROA-32.20% Target Price12.00 Perf Year-44.24%
Cash/sh2.01 P/C1.78 EPS next 5Y- ROE-66.60% 52W Range3.37 - 7.77 Perf YTD-51.75%
Dividend- P/FCF- EPS past 5Y5.70% ROI-38.40% 52W High-54.38% Beta1.26
Dividend %- Quick Ratio5.40 Sales past 5Y26.60% Gross Margin- 52W Low5.19% ATR0.33
Employees106 Current Ratio5.40 Sales Q/Q142.70% Oper. Margin- RSI (14)32.56 Volatility7.79% 8.20%
OptionableYes Debt/Eq0.00 EPS Q/Q44.30% Profit Margin- Rel Volume1.63 Prev Close3.58
ShortableYes LT Debt/Eq0.00 EarningsMay 06 BMO Payout- Avg Volume4.09M Price3.55
Recom1.90 SMA20-18.42% SMA50-25.46% SMA200-37.30% Volume1,061,632 Change-0.98%
Mar-21-22Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $6
Feb-11-22Initiated BMO Capital Markets Outperform $18
Dec-01-21Upgrade Jefferies Hold → Buy $7 → $12
Oct-26-20Resumed H.C. Wainwright Buy $11
Oct-02-20Upgrade Guggenheim Neutral → Buy $14
Sep-29-20Resumed JP Morgan Neutral
Dec-17-19Reiterated H.C. Wainwright Buy $5 → $9
Aug-13-19Reiterated H.C. Wainwright Buy $4 → $5
May-15-19Downgrade Guggenheim Buy → Neutral
May-06-19Upgrade H.C. Wainwright Neutral → Buy $7
May-06-19Upgrade Cowen Market Perform → Outperform
Mar-19-19Downgrade JP Morgan Neutral → Underweight
Mar-05-19Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-04-19Downgrade SVB Leerink Outperform → Mkt Perform
Mar-04-19Downgrade H.C. Wainwright Buy → Neutral $18 → $3.50
Mar-01-19Downgrade Piper Jaffray Overweight → Neutral $13 → $2.50
Mar-01-19Downgrade Jefferies Buy → Hold
Sep-07-18Initiated Piper Jaffray Overweight
Feb-08-18Resumed RBC Capital Mkts Outperform $12
Jan-31-18Initiated H.C. Wainwright Buy $18
May-23-22 07:59AM  
06:30AM  
May-10-22 04:30PM  
May-06-22 01:30PM  
07:45AM  
06:30AM  
May-03-22 08:55AM  
May-02-22 04:30PM  
Apr-28-22 11:18AM  
Apr-21-22 04:01PM  
Apr-01-22 04:30PM  
11:23AM  
Mar-31-22 04:30PM  
Mar-30-22 11:51AM  
Mar-29-22 06:30AM  
Mar-21-22 03:07PM  
03:00PM  
08:26AM  
Mar-19-22 07:15PM  
Mar-10-22 06:30AM  
Mar-01-22 04:30PM  
Feb-28-22 10:20AM  
Feb-27-22 09:16PM  
07:48AM  
Feb-25-22 07:45AM  
06:30AM  
Feb-23-22 04:30PM  
Feb-16-22 10:58AM  
10:46AM  
Feb-15-22 11:19AM  
06:40AM  
06:30AM  
Feb-10-22 04:01PM  
Feb-08-22 08:55AM  
Feb-04-22 04:30PM  
03:00PM  
Feb-01-22 04:30PM  
Jan-31-22 06:30AM  
Jan-06-22 04:34PM  
Jan-05-22 01:38PM  
Jan-04-22 10:00AM  
Jan-03-22 10:36PM  
04:30PM  
Dec-31-21 06:44AM  
Dec-29-21 04:30PM  
Dec-14-21 09:01AM  
Dec-12-21 09:30AM  
Dec-11-21 10:19PM  
06:00AM  
Dec-06-21 04:01PM  
Dec-02-21 12:00AM  
Dec-01-21 01:25PM  
10:06AM  
09:22AM  
Nov-30-21 04:33PM  
04:01PM  
12:48PM  
08:15AM  
06:30AM  
05:55AM  
02:11AM  
Nov-24-21 04:30PM  
Nov-17-21 04:01PM  
Nov-16-21 04:30PM  
06:30AM  
Nov-11-21 10:58AM  
Nov-04-21 09:00AM  
Nov-01-21 08:03PM  
04:04PM  
12:24PM  
09:11AM  
Oct-29-21 05:00PM  
07:45AM  
06:30AM  
Oct-22-21 03:00PM  
Oct-19-21 12:31PM  
Oct-14-21 04:01PM  
Oct-01-21 04:30PM  
Sep-22-21 04:01PM  
Aug-02-21 04:30PM  
09:19AM  
Jul-30-21 11:30AM  
07:55AM  
06:30AM  
Jul-23-21 03:00PM  
Jul-15-21 04:01PM  
Jul-13-21 08:38AM  
Jul-01-21 04:30PM  
Jun-10-21 02:09AM  
Jun-09-21 11:30AM  
Jun-01-21 04:30PM  
May-20-21 04:30PM  
May-19-21 05:00PM  
May-10-21 12:00PM  
11:03AM  
07:45AM  
06:30AM  
06:15AM  
May-03-21 04:30PM  
Apr-26-21 04:01PM  
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MITCHELL DEAN JDirectorSep 03Option Exercise3.8783,000321,40093,000Sep 03 04:06 PM